Sofosbuvir (formally labeled as PSI-797, GS-7977) is a phosphoramidate prodrug and nucleotide polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. It, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM), effective in vitro and in vivo. Multiple clinical trials demonstrated that treatments including sofosbuvir have higher sustained virologic response rates for genotypes 1, 2, 3, 4 and 6 in comparison with treatments that include only peginterferon and ribavirin. In addition, the side-effect profile of sofosbuvir and ribavirin dual treatment has an improved tolerability in comparison with treatment regimes that include interferon-based options.
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.